Is radical prostatectomy the preferred treatment for localized prostate cancer compared to other localized therapies?

Radical Prostatectomy vs. Other Localized Therapies for Localized Prostate Cancer

Radical prostatectomy and radiotherapy plus ADT are equally recommended as standard treatment options for intermediate and high-risk localized prostate cancer, with treatment selection based primarily on risk stratification rather than inherent superiority of one modality over the other. [1, @22@]

Risk-Stratified Treatment Approach

The choice between radical prostatectomy and other localized therapies depends critically on disease risk category, not on the superiority of surgery as a universal approach:

Low-Risk Disease

• Active surveillance is the preferred option for very low-risk disease (strong recommendation) and most low-risk patients (moderate recommendation). 1
• Definitive treatment (radical prostatectomy or radiotherapy) may be offered only to select low-risk patients with high probability of progression on surveillance. 1
• Single modality external beam radiotherapy or brachytherapy are appropriate radiation options. 1

Intermediate-Risk Disease

• Both radical prostatectomy and radiotherapy plus ADT are standard treatment options with Grade A evidence. 1
• For favorable intermediate-risk disease, radiation alone may be used, though the evidence is less robust than combining radiotherapy with ADT. 1
• Retrospective comparative studies suggest mortality reduction with surgery compared to external beam radiotherapy and brachytherapy, but these are not definitive given methodologic limitations. 1
• The RTOG 9408 trial demonstrated 10-year overall survival improvement from 54% to 61% (p=0.03) when ADT was added to radiotherapy for intermediate-risk patients. 1

High-Risk Disease

• Both radical prostatectomy and radiotherapy plus ADT (24-36 months) are standard treatment options with Grade A evidence. [1, @22@]
• The SPCG-4 trial showed 15-year all-cause mortality favored radical prostatectomy (46.1% vs 52.7%, RR 0.75) and prostate cancer-specific mortality (14.6% vs 20.7%, RR 0.62). 1
• In the PIVOT study, high-risk patients undergoing surgery had significantly lower prostate cancer-specific death (9.1% vs 17.5%). 1
• Active surveillance is not recommended for high-risk disease. 1

Critical Evidence Limitations

The evidence does not establish radical prostatectomy as universally superior to radiotherapy:

• No randomized controlled trials directly compare radical prostatectomy to modern dose-escalated radiotherapy with appropriate ADT. 1
• Retrospective registry studies suggesting surgery superiority have significant methodologic limitations including selection bias and confounding. 2
• A 2002 single-institution study with 1,682 patients found identical 8-year biochemical failure rates between radiotherapy and radical prostatectomy when analyzed with stringent definitions (72% vs 70%, p=0.96 in multivariate analysis). 3
• Treatment modality was not an independent predictor of treatment failure when controlling for PSA, Gleason score, and T stage. 3

Alternative Therapies: Not Standard Care

Focal ablative therapy, HIFU, and cryosurgery are not standard care options:

• These interventions lack comparative outcome evidence and should preferably be offered only within clinical trials. 1, 4
• A 2021 systematic review concluded there was insufficient high-certainty evidence for focal therapy effectiveness, with low confidence ratings across identified systematic reviews. 1
• For high-risk disease, cryosurgery, focal therapy, and HIFU are not recommended outside clinical trials. 1

Quality of Life Considerations

Functional outcomes differ between modalities and should inform shared decision-making:

• Robotic/laparoscopic prostatectomy is associated with less blood loss than retropubic approaches. 1
• Nerve-sparing techniques provide better erectile function recovery than non-nerve sparing. 1
• Older men experience higher rates of permanent erectile dysfunction and urinary incontinence after prostatectomy compared to younger men. 1
• ADT combined with radiation increases likelihood and severity of sexual dysfunction and causes systemic side effects. 1
• A 2026 study with ≥24 months follow-up showed RALRP provided superior bowel and hormonal outcomes, while IMRT yielded slightly better sexual function scores (though counteracted by ADT effects). 5
• Brachytherapy patients with obstructive lower urinary symptoms may prefer surgical approaches. 1

Common Pitfalls to Avoid

• Do not recommend neo-adjuvant ADT or systemic therapy before radical prostatectomy outside clinical trials (strong recommendation, Grade A). 1
• Do not add ADT to low-risk disease radiotherapy except for prostate size reduction for brachytherapy. 1
• Do not perform primary ADT for high-risk localized disease unless the patient has both limited life expectancy and local symptoms. 1
• Do not recommend observation/watchful waiting unless life expectancy ≤5 years for intermediate and high-risk disease. 1

Algorithmic Decision Framework

1. Establish risk category (low, favorable intermediate, unfavorable intermediate, high-risk) using PSA, Gleason score, and clinical stage. 1
2. Assess life expectancy: If ≤5 years, recommend observation/watchful waiting regardless of risk. 1
3. For low/very low-risk with >10 year life expectancy: Recommend active surveillance as preferred option. 1
4. For intermediate-risk with >10 year life expectancy: Offer radical prostatectomy OR radiotherapy plus ADT as equivalent standard options. 1
5. For high-risk with >5 year life expectancy: Offer radical prostatectomy OR radiotherapy plus 24-36 months ADT as equivalent standard options. [1, @22@]
6. Consider patient-specific factors: Age, comorbidities, baseline urinary/sexual/bowel function, and patient preferences regarding functional outcomes. 1
7. For unfavorable intermediate or high-risk undergoing surgery: Consider pelvic lymph node dissection and counsel regarding potential adjuvant radiotherapy. 1